{"id":936418,"date":"2026-02-12T07:03:42","date_gmt":"2026-02-12T12:03:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/"},"modified":"2026-02-12T07:03:42","modified_gmt":"2026-02-12T12:03:42","slug":"ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/","title":{"rendered":"Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026"},"content":{"rendered":"
\n

JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update.<\/p>\n\n\n\n\n\n\n\n\n\n\n
\n Conference Call and Webcast Information<\/strong>
\n \n <\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n
Date:\u00a0<\/td>\nThursday, February 26, 2026<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Time:\u00a0<\/td>\n8:30 AM Eastern Time<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Conference Call:<\/td>\n(800) 715-9871\u00a0(U.S. & Canada)
(646) 307-1963 (International)
Conference ID 3661098<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Webcast:<\/td>\nLive and replay webcasts of the call are available here<\/strong><\/a>.<\/td>\n<\/tr>\n<\/table>\n

\n
\n
About Ligand Pharmaceuticals<\/strong>
\n
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol\u00ae platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL\u2122 platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world\u2019s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com<\/u><\/a>. Follow Ligand on X<\/u><\/a> and LinkedIn<\/u><\/a>.<\/p>\n

We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n

Investors:
Melanie Herman
investors@ligand.com<\/u><\/a>
(858) 550-7761<\/p>\n

Media: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Kellie Walsh
media@ligand.com<\/u><\/a>
(914) 315-6072<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information \u00a0 Date:\u00a0 Thursday, February 26, 2026 \u00a0 \u00a0 Time:\u00a0 8:30 AM Eastern Time \u00a0 \u00a0 Conference Call: (800) 715-9871\u00a0(U.S. & Canada)(646) 307-1963 (International)Conference ID 3661098 \u00a0 \u00a0 Webcast: Live and replay webcasts of the call are available here. About Ligand Pharmaceuticals Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by … <\/p>\n

Continue reading “Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-936418","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLigand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information \u00a0 Date:\u00a0 Thursday, February 26, 2026 \u00a0 \u00a0 Time:\u00a0 8:30 AM Eastern Time \u00a0 \u00a0 Conference Call: (800) 715-9871\u00a0(U.S. & Canada)(646) 307-1963 (International)Conference ID 3661098 \u00a0 \u00a0 Webcast: Live and replay webcasts of the call are available here. About Ligand Pharmaceuticals Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by … Continue reading "Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-12T12:03:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjQ5MiM3NDE5ODg3IzIwMDY1NjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026\",\"datePublished\":\"2026-02-12T12:03:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\\\/\"},\"wordCount\":406,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjQ5MiM3NDE5ODg3IzIwMDY1NjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\\\/\",\"name\":\"Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjQ5MiM3NDE5ODg3IzIwMDY1NjQ=\",\"datePublished\":\"2026-02-12T12:03:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjQ5MiM3NDE5ODg3IzIwMDY1NjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MjQ5MiM3NDE5ODg3IzIwMDY1NjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/","og_locale":"en_US","og_type":"article","og_title":"Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - Market Newsdesk","og_description":"JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information \u00a0 Date:\u00a0 Thursday, February 26, 2026 \u00a0 \u00a0 Time:\u00a0 8:30 AM Eastern Time \u00a0 \u00a0 Conference Call: (800) 715-9871\u00a0(U.S. & Canada)(646) 307-1963 (International)Conference ID 3661098 \u00a0 \u00a0 Webcast: Live and replay webcasts of the call are available here. About Ligand Pharmaceuticals Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by … Continue reading \"Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-12T12:03:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjQ5MiM3NDE5ODg3IzIwMDY1NjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026","datePublished":"2026-02-12T12:03:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/"},"wordCount":406,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjQ5MiM3NDE5ODg3IzIwMDY1NjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/","name":"Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjQ5MiM3NDE5ODg3IzIwMDY1NjQ=","datePublished":"2026-02-12T12:03:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjQ5MiM3NDE5ODg3IzIwMDY1NjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MjQ5MiM3NDE5ODg3IzIwMDY1NjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ligand-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/936418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=936418"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/936418\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=936418"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=936418"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=936418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}